These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39183578)

  • 1. Mechanisms of resistance to daratumumab in patients with multiple myeloma.
    Iversen KF
    Basic Clin Pharmacol Toxicol; 2024 Oct; 135(4):401-408. PubMed ID: 39183578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
    Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
    Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
    Saltarella I; Desantis V; Melaccio A; Solimando AG; Lamanuzzi A; Ria R; Storlazzi CT; Mariggiò MA; Vacca A; Frassanito MA
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
    Nijhof IS; Casneuf T; van Velzen J; van Kessel B; Axel AE; Syed K; Groen RW; van Duin M; Sonneveld P; Minnema MC; Zweegman S; Chiu C; Bloem AC; Mutis T; Lokhorst HM; Sasser AK; van de Donk NW
    Blood; 2016 Aug; 128(7):959-70. PubMed ID: 27307294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
    Krejcik J; Casneuf T; Nijhof IS; Verbist B; Bald J; Plesner T; Syed K; Liu K; van de Donk NW; Weiss BM; Ahmadi T; Lokhorst HM; Mutis T; Sasser AK
    Blood; 2016 Jul; 128(3):384-94. PubMed ID: 27222480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells.
    Wang H; Koob T; Fromm JR; Gopal A; Carter D; Lieber A
    Cancer Biol Ther; 2024 Dec; 25(1):2314322. PubMed ID: 38361357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.
    van de Donk NW; Janmaat ML; Mutis T; Lammerts van Bueren JJ; Ahmadi T; Sasser AK; Lokhorst HM; Parren PW
    Immunol Rev; 2016 Mar; 270(1):95-112. PubMed ID: 26864107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Daratumumab for multiple myeloma].
    Croizier C; Bailly S
    Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
    Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
    Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.
    Kitadate A; Terao T; Narita K; Ikeda S; Takahashi Y; Tsushima T; Miura D; Takeuchi M; Takahashi N; Matsue K
    Cancer Sci; 2021 Sep; 112(9):3645-3654. PubMed ID: 34288263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
    Plesner T; van de Donk N; Richardson PG
    Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
    Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
    Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab for the treatment of multiple myeloma.
    Touzeau C; Moreau P
    Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti CD38 monoclonal antibodies for multiple myeloma treatment.
    Gozzetti A; Ciofini S; Simoncelli M; Santoni A; Pacelli P; Raspadori D; Bocchia M
    Hum Vaccin Immunother; 2022 Nov; 18(5):2052658. PubMed ID: 35404740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
    Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
    Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.